US Industry Fears Blocking Bill Would Weaken Exclusivity
Executive Summary
US industry fears draft legislation would weaken the 180-day exclusivity incentive to challenge patents; but it is more positive about planned reforms to rebate frameworks.
Topics
- Subjects
- Legislation
- Generic Drugs
- Biosimilars
- Intellectual Property
- Regions
- North America
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB140047
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB140047
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.